Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia

E Puigdecanet, B Espinet, J Lozano, L Sumoy, B Bellosillo, L Arenillas, A Álvarez-Larrán, F Solé, S Serrano, C Besses and L Florensa Laboratori de Citogenètica i Biologia Molecular, Servei de Patologia. Hospital del Mar, IMAS, Barcelona, Spain; Laboratori de Citologia Hematològica, Servei de Patologia, Hospital del Mar, IMAS, Barcelona, Spain; GRETNHE, IMIM-Hospital del Mar, Barcelona, Spain; Departament de Biologia Cellular, Fisiologia i Immunologia. Facultat de Biociències. Universitat Autònoma de Barcelona, Bellaterra, Spain; Escola de Citologia Hematològica Soledad Woessner-IMAS, Barcelona, Spain; Laboratori de Microarrays, Programa de Bioinformàtica i Genòmica, Centre de Regulació Genòmica-UPF, Barcelona, Spain; Plataforma de Bioinformática, CIBERehd, Hospital Clinic, Barcelona, Spain and Servei d’Hematologia Clı́nica, Hospital del Mar, IMAS, Barcelona, Spain

[1]  B. Nilsson,et al.  Gene expression analysis of BCR/ABL1‐dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation , 2008, Genes, chromosomes & cancer.

[2]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[3]  B. Bellosillo,et al.  JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis , 2007, Haematologica.

[4]  H. Pahl,et al.  JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. , 2007, Experimental hematology.

[5]  T. Barbui,et al.  V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. , 2007, Experimental hematology.

[6]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[7]  P. Campbell,et al.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.

[8]  S. Serrano,et al.  JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients , 2006, Leukemia.

[9]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[10]  Joaquín Dopazo,et al.  BABELOMICS: a systems biology perspective in the functional annotation of genome-scale experiments , 2006, Nucleic Acids Res..

[11]  N. Villamor,et al.  Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. , 2006, Haematologica.

[12]  M. Cazzola,et al.  Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. , 2005, Blood.

[13]  C. Steidl,et al.  Distinct Gene Expression Pattern of Malignant Hematopoietic Stem and Progenitor Cells in Polycythemia Vera , 2005, Annals of the New York Academy of Sciences.

[14]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[15]  Jae K. Lee,et al.  Robust classification modeling on microarray data using misclassification penalized posterior , 2005, ISMB.

[16]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[17]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[18]  T. Maiwald,et al.  Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF‐E2 , 2005, British journal of haematology.

[19]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[20]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[21]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[22]  O. Silvennoinen,et al.  Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. , 2004, Blood.

[23]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[24]  C. Langford,et al.  Gene expression profiling in polycythemia vera using cDNA microarray technology. , 2003, Cancer research.

[25]  R. Cooney,et al.  Suppressors of Cytokine Signaling (SOCS): Inhibitors of the JAK/STAT Pathway , 2002, Shock.

[26]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[27]  A. Yoshimura,et al.  The Jak-Stat pathway in normal and perturbed hematopoiesis. , 2000, Blood.

[28]  A. Yoshimura,et al.  Proteasomes Regulate Erythropoietin Receptor and Signal Transducer and Activator of Transcription 5 (STAT5) Activation , 1998, The Journal of Biological Chemistry.

[29]  J. Sleeman,et al.  Two different functions for CD44 proteins in human myelopoiesis. , 1998, The Journal of clinical investigation.

[30]  P. Rameshwar,et al.  Implication of CD44 in adhesion‐mediated overproduction of TGF‐β and IL‐1 in monocytes from patients with bone marrow fibrosis , 1996, British journal of haematology.